Tirzepatide
Brand: Mounjaro, Zepbound
A once-weekly dual GIP and GLP-1 receptor agonist that produced the largest weight-loss and HbA1c reductions yet seen in phase-3 trials of an approved incretin drug.
Mounjaro (type 2 diabetes) and Zepbound (obesity, obstructive sleep apnea) are FDA-approved. Compounded tirzepatide is a separate, non-FDA-approved category.
What it is
Tirzepatide is a dual agonist — a single molecule that activates both the GIP and GLP-1 receptors. Combining the two incretin pathways appears to amplify the appetite- and glucose-lowering effects beyond what a GLP-1 agonist alone achieves, at least at the doses studied.
What it’s approved or studied for
It is FDA-approved for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and moderate-to-severe obstructive sleep apnea in adults with obesity. In head-to-head diabetes trials it outperformed semaglutide 1 mg on both HbA1c and weight.
What human evidence exists
The SURPASS (diabetes) and SURMOUNT (obesity, OSA) programs are large, randomized, and placebo- or active-controlled. Weight loss and glycemic outcomes are Grade A. Cardiovascular benefit is still Grade C pending the dedicated SURPASS-CVOT outcomes trial — plausible and directionally supported, but not yet proven on hard endpoints the way semaglutide’s has been.
The major unknowns
The cardiovascular outcomes trial has not reported, long-term durability and post-cessation weight regain mirror the GLP-1 class, and — as with all rapid weight loss — a meaningful fraction of the loss is lean tissue unless training and protein intake are managed.
Most important safety considerations
Gastrointestinal effects dominate the side-effect profile and ease with slow titration. The rodent-based thyroid C-cell boxed warning applies; medullary thyroid carcinoma history and MEN 2 are contraindications. This is a research summary, not medical advice — decisions belong with a clinician.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Up to ~21% mean body-weight loss at the highest dose. — SURMOUNT-1 (NEJM 2022) reported up to −20.9% at 72 weeks on 15 mg in adults with obesity without diabetes.
Superior HbA1c reduction vs semaglutide in a head-to-head trial. — SURPASS-2 (NEJM 2021) showed greater HbA1c and weight reduction than semaglutide 1 mg.
Approved after trials showed reduced apnea-hypopnea index. — SURMOUNT-OSA led to FDA approval for moderate-to-severe OSA in adults with obesity.
A dedicated outcomes trial is ongoing. — Cardiovascular benefit is biologically plausible and supported by risk-factor improvements, but the definitive MACE trial (SURPASS-CVOT) has not yet reported.
Not a benefit — some lean mass is lost with fat.
Safety
Common adverse effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
Serious risks
- Pancreatitis (uncommon)
- Gallbladder disease
- Thyroid C-cell tumors (seen in rodents; boxed warning)
- Severe gastrointestinal reactions
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Known hypersensitivity to tirzepatide
References